HHS released an advisory opinion regarding certain manufacturer’s refusal to sell 340B drugs through a contract pharmacy. See documents attached. “The Office of the General
https://www.pharmacytimes.com/news/landmark-supreme-court-ruling-state-regulation-of-pbm-reimbursement-rates This will help protect the recent trend by the PBM’s to lower the reimbursement for a 340B drug dispensed vs a non-340B drug. Already
Health Resources and Services Administration (HRSA) released the procedures and requirements for the 340B Program’s Administrative Dispute Resolution (“ADR”). This has been 10 years in
Hospitals Sue HHS over Pharma 340B Pricing for contract Pharmacy attack.See complaint attached.
US House letter to HHS regarding Kalderos and their new program called “340B Pay”. 340B Pay will uproot the current 340B cash flow model and
Health Centers Sue HHS over Pharma 340B Pricing for Contract Pharmacy attack.See complaint attached.
RWC-340B and 340B Grantee Plaintiffs File Lawsuit Against HHS/HRSA to Protect 340B Contract Pharmacy Program from Manufacturer Attacks. See complaint attached.
AstraZeneca and Sanofi Block Access to 340B Contract Pharmacy Pricing but not Novartis. See the letter from Sanofi attached.
HHS letter to Eli Lilly in response to their 340B price restrictions. HHS Tells Lilly, Don’t assume we agree on your position about 340B. See
U.S. senators wrote to the U.S. Health and Human Services (HHS) to urge the U.S. Health Resources and Services Administration (HRSA) “to take immediate action
